Singapore Markets close in 7 hrs 44 mins

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
14.81+0.17 (+1.16%)
At close: 04:00PM EDT
14.74 -0.07 (-0.47%)
After hours: 07:53PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 2.29
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 319.99
52-week low 37.61
50-day moving average 311.26
200-day moving average 312.90

Share statistics

Avg vol (3-month) 33.17M
Avg vol (10-day) 34.06M
Shares outstanding 5179.94M
Implied shares outstanding 6N/A
Float 8167.32M
% held by insiders 10.97%
% held by institutions 173.40%
Shares short (14 Jul 2022) 431.46M
Short ratio (14 Jul 2022) 48.62
Short % of float (14 Jul 2022) 419.02%
Short % of shares outstanding (14 Jul 2022) 416.95%
Shares short (prior month 14 Jun 2022) 429.69M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin -103.16%
Operating margin (ttm)-93.76%

Management effectiveness

Return on assets (ttm)-27.13%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)188.03M
Revenue per share (ttm)1.04
Quarterly revenue growth (yoy)161.90%
Gross profit (ttm)-58.9M
EBITDA -175.38M
Net income avi to common (ttm)-193.97M
Diluted EPS (ttm)-1.27
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)443.47M
Total cash per share (mrq)2.39
Total debt (mrq)613M
Total debt/equity (mrq)N/A
Current ratio (mrq)6.32
Book value per share (mrq)-0.82

Cash flow statement

Operating cash flow (ttm)-158.95M
Levered free cash flow (ttm)-143.19M